Traders should expect the stock to trade near $27.00 adjusted for the time value of money and deal risk. Monitor for regulatory filings (HSR, German and Italian antitrust) and any competing bids. The spread may widen if regulatory concerns emerge, but the deal is not financing-contingent.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Apr 29 $26.67entry
- T+1 · 7mo ago −0.04%α −1.06% · $26.66
- T+5 · 7mo ago +0.15%α −2.96% · $26.71
- T+20 · 6mo ago +0.45%α −5.01% · $26.79
- T+60 · due 4mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Chiesi Farmaceutici will acquire KalVista for $27.00 per share in cash, valuing the company at approximately $1.9 billion. The offer represents a 36% premium to the 30-day VWAP, and the transaction is expected to close in Q3 2026, subject to regulatory approvals and minimum tender conditions.
Key Financial Metrics
Key Facts
- Offer price: $27.00 per share in cash
- Total equity value: ~$1.9 billion
- 36% premium to 30-day VWAP as of April 28, 2026
- Transaction not subject to financing condition
- Expected closing in Q3 2026
- Minimum tender condition: >50% of outstanding shares
- Termination fee: $66.4 million payable by KalVista in certain circumstances
- KalVista board unanimously approved and recommends shareholders tender
Financial Impact
KalVista shareholders will receive $27.00 per share, a 36% premium to recent trading levels, implying an enterprise value of approximately $1.9 billion.
Risk Factors
- Regulatory approvals from HSR, German Bundeskartellamt, and Italian foreign investment authorities
- Minimum tender condition (more than 50% of shares tendered)
- Potential competing superior proposal triggering termination fee
- Delays or failure to obtain necessary clearances
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-017656 |
| Document: ef20071670_8k.htm | 0001140361-26-017656 |
| Document: ef20071670_ex99-1.htm | 0001140361-26-017656 |
| Document: 0001140361-26-017656-index-headers.html | 0001140361-26-017656 |
| Document: 0001140361-26-017656-index.html | 0001140361-26-017656 |
| Document: 0001140361-26-017656.txt | 0001140361-26-017656 |
Track record
12 reports on KALV
2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +4.15% at T+5 after the Apr 17, 2026 report. 2 of 5 went positive at some point.
Filters
- Jun 22, 202621w ago 15-12G Bearish 7/10 No price data
- Jun 17, 202621w ago EFFECT Neutral 3/10 Entry $27.00 No price data
- Jun 11, 202622w ago 8-K Neutral 5/10 Entry $26.99 No price data
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $27.00 No price data
- May 19, 202625w ago Insider Cluster Bearish 5/10 Entry $26.81 to $26.79 ▲ +0.07% +1.31% vs SPY
- May 19, 202625w ago Insider Cluster Neutral 2/10 Entry $26.81 to $26.79 ▼ −0.07% −1.31% vs SPY
- Apr 29, 202628w ago 8-K Bullish 8/10 Viewing Entry $26.67 to $26.71 ▲ +0.15% −2.96% vs SPY
- Apr 17, 202630w ago Insider Cluster Bearish 6/10 Entry $20.48 to $19.63 ▲ +4.15% +4.71% vs SPY
- Feb 23, 202638w ago Insider Cluster Bearish 6/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
- Feb 23, 202638w ago Insider Cluster Bearish 7/10 Entry $15.56 to $16.06 ▼ −3.21% −2.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers